Nutriband

NTRB

市值 US$7561萬

ORLANDO, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), announced today that it has seen 272,671 NTRBW warrants exercised at a strike price of $6.43 for proceeds to the company of $1,753,274.53.

Nutriband files new non-provisional patent application to strengthen intellectual property protection of its AVERSA™ transdermal abuse deterrent technology being developed for patches containing  opioids and stimulants with a potential for abuse. Nutriband's AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.

Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary CEO letter reflects on five years of milestones since the Company's October 1, 2021 uplisting, as AVERSA™ Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled ORLANDO, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) today announced that CEO Gareth Sheridan has published a letter to shareholders marking the fifth anniversary of the Company's listing on the Nasdaq Capital Market, which took effect on October 1, 2021.

ORLANDO, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its CEO, Gareth Sheridan, has been featured in a new documentary by independent journalist and filmmaker Nick Shirley examining the ongoing opioid crisis in the United States.

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled.

ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th.

Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.

ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26th as part of the CEO spotlight event.

Nutriband's Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens, Amazon.com, Inc., Cardinal Health and Other Major National Retailers ORLANDO, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) and its wholly owned subsidiary Active Intelligence (“Active Intelligence” or the “Company”), an emerging leader in innovative wellness, recovery, and performance-focused consumer products, today announced its participation in the upcoming ECRM conference taking place in June 2026, where the Company will showcase its latest AI-branded product portfolio to buyers and executives from some of the nation's largest retail and healthcare organizations.

ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company's AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications.